# Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial

> **NCT03500328** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Johns Hopkins University** · enrollment: 900 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **OTHER:** Natalizumab/natalizumab-sztn, Alemtuzumab, Ocrelizumab, Rituximab/rituximab-arrx/rituximab-abbs/rituximab-pvvr, Cladribine, Ofatumumab, Ublituximab-xiiy, Ocrelizumab and hyaluronidase-ocsq
- **OTHER:** Glatiramer acetate, Interferons (intramuscular, subcutaneous, pegylated) Teriflunomide, Fumarates (dimethyl, diroximel, monomethyl) Fingolimod, Siponimod, Ozanimod, Ponesimod

## Key facts

- **NCT ID:** NCT03500328
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-05-02
- **Primary completion:** 2026-08-01
- **Final completion:** 2026-08-01
- **Target enrollment:** 900 (ACTUAL)
- **Last updated:** 2025-10-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03500328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03500328, "Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03500328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*